Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling.

Ellero-Simatos S, Szymańska E, Rullmann T, Dokter WH, Ramaker R, Berger R, van Iersel TM, Smilde AK, Hankemeier T, Alkema W.

Genome Med. 2012 Nov 30;4(11):94. doi: 10.1186/gm395. eCollection 2012.

2.

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.

van Genugten RE, van Raalte DH, Muskiet MH, Heymans MW, Pouwels PJ, Ouwens DM, Mari A, Diamant M.

Eur J Endocrinol. 2014 Feb 4;170(3):429-39. doi: 10.1530/EJE-13-0610. Print 2014 Mar.

3.

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.

van Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJ, Ackermans MT, Sauerwein HP, Serlie MJ, Diamant M.

Diabetologia. 2011 Aug;54(8):2103-12. doi: 10.1007/s00125-011-2174-9. Epub 2011 May 12.

4.

Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial.

van Raalte DH, Diamant M, Ouwens DM, Ijzerman RG, Linssen MM, Guigas B, Eringa EC, Serné EH.

Diabetologia. 2013 Nov;56(11):2383-91. doi: 10.1007/s00125-013-3016-8. Epub 2013 Aug 11.

PMID:
23933953
5.

Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, Nässander UK, Heine RJ, Mari A, Dokter WH, Diamant M.

Eur J Endocrinol. 2010 Apr;162(4):729-35. doi: 10.1530/EJE-09-1034. Epub 2010 Feb 2.

6.

Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.

den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JW, Hoes JN, Dijkmans BA, Diamant M.

Arthritis Rheum. 2012 Mar;64(3):639-46. doi: 10.1002/art.33378.

7.

Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans.

Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, Pørksen N.

Diabetologia. 2002 Jan;45(1):49-55.

PMID:
11845223
8.

Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.

van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A, van der Greef J.

Br J Clin Pharmacol. 2007 May;63(5):562-74.

9.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
10.

Prednisolone-induced changes in gene-expression profiles in healthy volunteers.

Toonen EJ, Fleuren WW, Nässander U, van Lierop MJ, Bauerschmidt S, Dokter WH, Alkema W.

Pharmacogenomics. 2011 Jul;12(7):985-98. doi: 10.2217/pgs.11.34. Epub 2011 Jun 2.

PMID:
21635145
11.

Angiopoietin-like protein 4 is differentially regulated by glucocorticoids and insulin in vitro and in vivo in healthy humans.

van Raalte DH, Brands M, Serlie MJ, Mudde K, Stienstra R, Sauerwein HP, Kersten S, Diamant M.

Exp Clin Endocrinol Diabetes. 2012 Nov;120(10):598-603. doi: 10.1055/s-0032-1321864. Epub 2012 Sep 12.

PMID:
22972030
12.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
13.

Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?

van Raalte DH, Kwa KA, van Genugten RE, Tushuizen ME, Holst JJ, Deacon CF, Karemaker JM, Heine RJ, Mari A, Diamant M.

Metabolism. 2013 Apr;62(4):568-77. doi: 10.1016/j.metabol.2012.10.007. Epub 2012 Nov 17.

PMID:
23164480
14.

Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.

Bertagna X, Escourolle H, Pinquier JL, Coste J, Raux-Demay MC, Perles P, Silvestre L, Luton JP, Strauch G.

J Clin Endocrinol Metab. 1994 Feb;78(2):375-80.

PMID:
8106625
15.

No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoid-induced insulin resistance in healthy men.

Brands M, van Raalte DH, João Ferraz M, Sauerwein HP, Verhoeven AJ, Aerts JM, Diamant M, Serlie MJ.

J Clin Endocrinol Metab. 2013 Mar;98(3):1219-25. doi: 10.1210/jc.2012-3266. Epub 2013 Feb 5.

PMID:
23386653
16.

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR.

J Clin Endocrinol Metab. 1998 Feb;83(2):320-5.

PMID:
9467534
17.

In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.

Diederich S, Quinkler M, Mai K, Schöneshöfer M, Baehr V, Pfeiffer A, Oelkers W, Eigendorff E.

Horm Metab Res. 2011 Jan;43(1):66-71. doi: 10.1055/s-0030-1267170. Epub 2010 Oct 5.

PMID:
20925019
18.

Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects.

Babadjanova G, Allolio B, Vollmer M, Reincke M, Schulte HM.

Eur J Clin Pharmacol. 1996;51(1):53-7.

PMID:
8880052
19.

Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling.

Diémé B, Halimi JM, Emond P, Büchler M, Nadal-Desbarat L, Blasco H, Le Guellec C.

Transplantation. 2014 Jul 27;98(2):195-201. doi: 10.1097/TP.0000000000000039.

PMID:
24598938
20.
Items per page

Supplemental Content

Write to the Help Desk